The Globe and Mail reports in its Thursday, Aug. 16, edition that Canaccord Genuity analyst Matt Bottomley says Cronos Group ($8.36) is set to become a "meaningful" player in the cannabis industry. The Globe's David Leeder writes in the Eye On Equities column that Mr. Bottomley, despite believing valuations in the weed sector are currently "more indicative of fair value at this time," upgraded Cronos to "hold" from "sell" in the wake of Tuesday's release of in-line second quarter financial results. Mr. Bottomley boosted his share target to $7.50 from $6.50. Analysts on average target the shares at $8.70. Mr. Bottomley says in a note: "Over the past several months, we believe Cronos has added a number of compelling strategic initiatives to the mix, including: a supply agreement into Poland's recently legalized medical market; a partnership with MedMen that could provide insights on consumer trends and potential access to retail in Canada; the creation of Cronos GrowCo that will increase the company's potential capacity for intentional export; and a recent take-or-pay supply agreement with U.S.-based Cura Select (should the company receive a license in Canada)."